Samarium (153Sm) lexidronam pentasodium

N/A

Report date: 2023/03/22 15:01:59
NME

Base Information

Drug NameSamarium (153Sm) lexidronam pentasodium
Drug Alias NameSamarium[153Sm] Lexidronam来昔决南钐[153Sm]QuadrametCYT-424SHR-3644 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIonising radiation emittersReactive oxygen species stimulants
TargetsReactive oxygen species
Therapy Area/IndicationsBone metastasesPainNeoplasm Metastasis +[5] 
Global Approved IndicationsPainNeoplasm Metastasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/03/28
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesThe Dow Chemical Company
China Registration ClassN/A

Develop Information

Active CompaniesCis Bio International Sa
Inactive CompaniesLouisiana State University Health Sciences Center ShreveportNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsPain
Inactive IndicationsBone metastasesNeoplasm MetastasisProstatic Neoplasms +[4] 

Other Information

ATC CodeV10BX02
Related LinksWikipediaDrugBankKEGG